Repligen (RGEN) Cash & Equivalents (2010 - 2026)

Repligen (RGEN) has 17 years of Cash & Equivalents data on file, last reported at $784.5 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 12.52% year-over-year to $784.5 million in Q1 2026; TTM through Mar 2026 was $784.5 million, a 12.52% increase from a year earlier, with the FY2025 full-year figure at $767.6 million, up 1.36% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $784.5 million, up from $767.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for RGEN reached as high as $809.1 million in Q2 2024 and fell as low as $516.6 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $683.4 million across 5 years, with a median of $708.9 million in 2025.
• Across the five-year window, Cash & Equivalents decreased 18.77% in 2022 and surged 51.1% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $523.5 million in 2022, then jumped by 43.53% to $751.3 million in 2023, then rose by 0.8% to $757.4 million in 2024, then increased by 1.36% to $767.6 million in 2025, then advanced by 2.2% to $784.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $784.5 million in Q1 2026, $767.6 million in Q4 2025, and $748.7 million in Q3 2025.